D745 + D150 + D029

D745 + D150 + D029 is an experimental oral fixed-dose combination investigated for its pharmacokinetics and safety in healthy subjects, primarily in the context of type 2 diabetes and related metabolic disorders. Based on available clinical trial data, D745, D150, and D029 each likely represent individual drug components, but their exact identities are not directly provided in public sources. In related trials conducted by Chong Kun Dang Pharmaceutical, these codes are frequently referenced alongside antidiabetic agents such as lobeglitazone, sitagliptin, and metformin, suggesting that D745, D150, and D029 may be code names for agents within these or related therapeutic classes. The mechanism of action is likely antidiabetic, with potential actions on insulin sensitization and/or incretin modulation, but precise mechanisms and targets for each code are not explicitly publicly disclosed[2][4][6].